ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
Accrued Liabilities
ADC Therapeutics SA
Accrued Liabilities Peer Comparison
Competitive Accrued Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ADC Therapeutics SA
NYSE:ADCT
|
Accrued Liabilities
$39.1m
|
CAGR 3-Years
48%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
AC Immune SA
NASDAQ:ACIU
|
Accrued Liabilities
CHf11.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Accrued Liabilities
$61m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Accrued Liabilities
CHf17.7m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
6%
|
|
Idorsia Ltd
SIX:IDIA
|
Accrued Liabilities
CHf133.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Kuros Biosciences AG
SIX:KURN
|
Accrued Liabilities
CHf7.9m
|
CAGR 3-Years
44%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Accrued Liabilities?
Accrued Liabilities
39.1m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Accrued Liabilities amounts to 39.1m USD.
What is ADC Therapeutics SA's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
51%
Over the last year, the Accrued Liabilities growth was 140%. The average annual Accrued Liabilities growth rates for ADC Therapeutics SA have been 48% over the past three years , 51% over the past five years .